Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway

This publication has 35 references indexed in Scilit:

• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
  Journal of Clinical Oncology, 2012
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2012
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
  Science Translational Medicine, 2012
• Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis
  Journal of Oncology, 2012
• A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
  Cancer Research, 2011
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
  Proceedings of the National Academy of Sciences, 2011
• EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
  New England Journal of Medicine, 2010
• The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells
  Breast Cancer Research and Treatment, 2010
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
  Nature, 2007
• Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
  The Lancet, 2004